Novocure
PORTSMOUTH, New Hampshire, December 2, 2011 -
Four clinical sites in the U.S.
WASHINGTON, April 15, 2011 - Novocure today announced that the U.S.
MONTREAL, November 19, 2010 - Data presented today from a pivotal, phase III randomized clinical trial
for patients with recurrent glioblastoma tumors suggest that Tumor Treating
Fields (TTF) therapy may increase median survival time and improve quality of
life scores compared to best standard of care chemotherapy.
MILAN, October 10, 2010 - Novocure reported today that patients with advanced non-small cell lung
cancer (NSCLC) achieved a significant increase in survival time when tumor
treating fields (TTF) therapy was added to chemotherapy, as compared to
previously reported outcomes for patients receiving chemotherapy alone.
